TITLE

Rituximab for Immune Cytopenia in Adults: Idiopathic Thrombocytopenic Purpura, Autoimmune Hemolytic Anemia, and Evans Syndrome

AUTHOR(S)
Shanafelt, Tait D.; Madueme, Hans L.; Wolf, Robert C.; Tefferi, Ayalew
PUB. DATE
November 2003
SOURCE
Mayo Clinic Proceedings;Nov2003, Vol. 78 Issue 11, p1340
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
• Objective: To evaluate the efficacy of rituximab for the treatment of adult patients with immune cytopenia, including idiopathic thrombocytopenic purpura (ITP), autoimmune hemolytic anemia, and Evans syndrome. • Patients and Methods: We retrospectively reviewed the medical charts of all patients treated with rituximab for immune cytopenia at the Mayo Clinic in Rochester, Minn, through January 1, 2003. Fourteen patients (median age at first diagnosis, 51 years; range, 21-79 years) were identified who received 1 or more treatment courses of rituximab for treatment of refractory ITP (12 patients), autoimmune hemolytic anemia (AIHA) (5 patients), or both ITP and AIHA (classified as Evans syndrome) (4 patients). Data regarding age, diagnosis, date of diagnosis, previous treatments, comorbid conditions, blood cell counts before taking rituximab, number of rituximab treatments, and response to treatment were extracted and analyzed. • Results: Of 12 patients treated for ITP, 6 were receiving corticosteroid-based treatment either alone or combined with other immunosuppressive therapy at the time they received rituximab. Complete remission occurred in 5 (42%) of 12 patients with ITP and in 2 (40%) of 5 patients with AIHA. Response to rituximab in patients with Evans syndrome was seen in either ITP or AIHA, but not both. Complete response was often durable in ITP. Responses were seen in both splenectomized and nonsplenectomized patients. • Conclusions: Our findings, considered with the results of other studies, suggest that rituximab deserves early consideration as salvage therapy for immune cytopenias that are refractory to both corticosteroid treatment and splenectomy. This series represents the largest series of adult patients with AIHA and Evans syndrome.
ACCESSION #
11286190

 

Related Articles

  • Rituximab in pemphigus. Kanwar, Amrinder J.; Vinay, Keshavamurthy // Indian Journal of Dermatology, Venereology & Leprology;Nov/Dec2012, Vol. 78 Issue 6, p671 

    The author comments on the Rituximab management of pemphigus, a chronic, muco-cutaneous autoimmune blistering disorder. Pemphigus has two main variants: pemphigus vulgaris (PV) and pemphigus foliaceus (PF). Varying between 75 to 92% of total pemphigus patients, PV is the most common subtype...

  • Biomarkers in Juvenile Idiopathic Arthritis: Translating Disease Mechanisms into Diagnostic Tools. Foell, Dirk; Däbritz, Jan // International Journal of Advances in Rheumatology;2011, Vol. 9 Issue 1, p8 

    Juvenile idiopathic arthritis (JIA) is the most common, chronic rheumatic disease in children, with the current classification for JIA distinguishing various subtypes of disease. The disease often takes a remitting course, requires immunosuppression for many years, and has a long-term outcome...

  • Policondritis recidivante asociada a linfoma linfoplasmocítico y eritema nudoso. Castrejón, Isabel; Ibáñez, Mónica; Vicente, Esther; Steegmann, Juan Luis; Castañeda, Santos // Reumatologia Clinica;ene2007, Vol. 3 Issue 1, p45 

    Relapsing polychondritis is a disease of unknown etiology characterized by episodic inflammation of cartilaginous tissues. More rarely, it has been described as a paraneoplastic phenomenon mainly associated with myelodysplastic syndromes or other haematologic diseases. We present a case of...

  • Prednisolone/rituximab.  // Reactions Weekly;Sep2015, Vol. 1569 Issue 1, p175 

    The article present two case studies of a 60-year-old woman and a 42-year-old woman with immunoglobulin (Ig) G4-related diseases, who were treated with prednisolone and rituximab and mentions that the 42-year old woman developed herpes zoster during rituximab treatment.

  • An immunofluorescence test for phospholipase-A2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Hoxha, Elion; Harendza, Sigrid; Zahner, Gunter; Panzer, Ulf; Steinmetz, Oliver; Fechner, Kai; Helmchen, Udo; Stahl, Rolf A.K. // Nephrology Dialysis Transplantation;Aug2011, Vol. 26 Issue 8, p2526 

    Background. The recent finding that phospholipase-A2-receptor antibodies (PLA2R-AB) may play a role in the development of primary membranous glomerulonephritis (MGN) offers the opportunity to measure a marker to help diagnose, classify and eventually monitor the course of patients with...

  • SUCCESFULL TREATMENT OF REFRACTORY IDIOPATHIC THROMBOCYTOPENIC PURPURA WITH RITUXIMAB. Jamaković, Mesud; Bijedić, Vildan M.; Vila, Meliha; Burazerović, Lejla; Polimac-Sefo, Nedžla // Medical Journal;Apr-Jun2012, Vol. 18 Issue 2, p135 

    Idiopathic thrombocytopenic purpura (ITP) is immunologically mediated disease caused by large number of infective, pharmacologic and other agents. Severe forms of disorder can result in heavy, uncontrolled and occasionally life-threatening bleedings. Since mild forms of disease are generally not...

  • Secondary Hemophagocytic Syndrome Associated with Richter's Transformation in Chronic Lymphocytic Leukemia. El-Haj, Nura; Gonsalves, Wilson I.; Gupta, Vinay; Smeltzer, Jacob P.; Parikh, Sameer A.; Singh, Preet P.; Gangat, Naseema // Case Reports in Hematology;2014, p1 

    Hemophagocytic syndrome (HPS) is an extremely rare condition arising from the overactivation of one's own immune system. It results in excessive inflammation and tissue destruction. Prompt initiation of treatment is warranted in either scenario in order to decrease mortality. Most cases are...

  • Clinical, biological and ultrasonographic remission in a patient with musculoskeletal systemic lupus erythematosus with rituximab. Torrente-Segarra, V.; Lisbona-Pérez, M. P.; Rotes-Sala, D.; Castro-Oreiro, S.; Carbonell-Abelló, J. // Lupus;Mar2009, Vol. 18 Issue 3, p270 

    Systemic lupus erythematosus (SLE) is a multiorganic autoimmune disease that affects skin, osteoarticular and kidney frequently. Rituximab showed efficacy in treatment of osteoarticular and haematological SLE, but its use has been generalised for renal disease. In our case, we showed efficacy of...

  • SYSTEMIC LUPUS ERYTHEMATOSUS — AN IMMUNOLOGICAL DISORDER: CLINICAL PRESENTATIONS AND THERAPEUTIC OPTIONS. AFZAL, N.; SHEHZAD, F.; RASHEED, S. // Biomedica;Sep2014, Vol. 30 Issue 3, p1 

    Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by production of numerous autoantibodies and damage to multiple organs and systems. SLE most often affects heart, joints, skin, lungs, blood vessels, liver, and kidneys. SLE is seen in young women of childbearing age (20...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics